135 related articles for article (PubMed ID: 7905522)
1. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
Richman DD; Meng TC; Spector SA; Fischl MA; Resnick L; Lai S
J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):135-8. PubMed ID: 7905522
[TBL] [Abstract][Full Text] [Related]
2. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
5. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
7. 3TC/AZT: just another combination.
GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
Kaulen P; Pham DT; Baranowski E; Wollensak J
Ger J Ophthalmol; 1993 Nov; 2(6):412-5. PubMed ID: 8312826
[TBL] [Abstract][Full Text] [Related]
9. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
[TBL] [Abstract][Full Text] [Related]
10. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
[TBL] [Abstract][Full Text] [Related]
12. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine (3TC) approved for combination use with AZT.
James JS
AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
[TBL] [Abstract][Full Text] [Related]
14. AZT studies reinforce benefits of combination.
AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
Richman DD
Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629
[TBL] [Abstract][Full Text] [Related]
16. [Sequential dideoxycytidine and zidovudine in advanced HIV-1 infection. Phase II study].
Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L
Rev Invest Clin; 1993; 45(2):145-7. PubMed ID: 8393211
[TBL] [Abstract][Full Text] [Related]
17. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Fischl MA; Olson RM; Follansbee SE; Lalezari JP; Henry DH; Frame PT; Remick SC; Salgo MP; Lin AH; Nauss-Karol C; Lieberman J; Soo W
Ann Intern Med; 1993 May; 118(10):762-9. PubMed ID: 8097082
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
Spector SA; Ripley D; Hsia K
Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
20. Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
Basham T; Holdener T; Merigan T
J Infect Dis; 1991 Apr; 163(4):869-72. PubMed ID: 1849164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]